STAT3 and neoplasm: These findings indicated that the increased efficacy of BIS-siRNA delivery techniques might advance the therapeutic application of BIS targeted to suppress tumor progression by inhibiting the anti-apoptotic effect of BIS, as well as STAT3-mediated CSC progression.